DICE Therapeutics’ $345 Million Public Offering

Wilson Sonsini Goodrich & Rosati advised DICE Therapeutics on the deal.DICE Therapeutics, Inc., a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Martina Bellini

Author: Martina Bellini

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here